Drug pair eliminated breast cancer tumors in animals’ bones
In animal experiments, blocking a signaling protein and stimulating immune cells also produced lasting immune memory when the animals faced cancer again.
Limit: The abstract does not report drug doses or treatment duration
Edited by Boris Djordjevic · AgingResearch.News
In animal experiments on breast cancer that had spread to bone, researchers targeted senescent fibroblasts, support cells that had stopped dividing. These cells produced immune-suppressing signals that depended on a signaling protein.
Removing these cells, genetically eliminating the protein from them or blocking it with a drug suppressed metastasis and expanded certain immune-cell populations. But one group of immune cells still lacked a signal needed to stimulate immune activity. Researchers combined a drug that blocked the protein with a drug that stimulated T cells, which help the immune system fight cancer. The combination eradicated bone metastases in an antigen-specific manner, meaning the effect was specific to particular molecules recognized by the immune system. The animals also showed lasting immune memory when challenged with cancer again.
Why it matters
Cell senescence is a process relevant to aging. The authors propose targeting its immune-suppressing signals alongside immune stimulation to tackle breast cancer that has spread to bone.
Caveats
These animal experiments do not establish benefit in people. The preprint has not been peer-reviewed, and the abstract does not report the animal species, doses or treatment duration.
- Genetic ablation of senescent cancer-associated fibroblasts
- MK2 inhibitor
- MAPKAPK2
- TNFRSF4
- Breast cancer
- Humans
The paper
Targeting MK2-Driven Stromal Senescence Sensitizes Breast Cancer Bone Metastasis to Immunotherapy
Washington University School of Medicine; Washington University
bioRxiv, Oct 28, 2026, Open access, CC BY, Preprint, not peer-reviewed
